# Carmustine and O(6)-Benzylguanine in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme

> **NCT00046878** · PHASE2 · WITHDRAWN · sponsor: **Duke University**

## Conditions studied

- Brain and Central Nervous System Tumors

## Interventions

- **DRUG:** O6-benzylguanine
- **DRUG:** carmustine

## Key facts

- **NCT ID:** NCT00046878
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** 2002-08
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2013-03-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00046878

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00046878, "Carmustine and O(6)-Benzylguanine in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00046878. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*